Compugen Ltd. (NASDAQ:CGEN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “

Analyst Recommendations for Compugen (NASDAQ:CGEN)

Shares of Compugen (NASDAQ:CGEN) opened at 6.65 on Thursday. The stock’s 50 day moving average price is $6.13 and its 200-day moving average price is $6.60. Compugen has a 12 month low of $4.32 and a 12 month high of $7.79. The firm’s market capitalization is $338.54 million.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings results on Monday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Compugen had a negative net margin of 261.77% and a negative return on equity of 29.33%. On average, equities analysts anticipate that Compugen will post ($0.59) earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Compugen by 20.9% in the first quarter. Geode Capital Management LLC now owns 22,873 shares of the company’s stock valued at $127,000 after buying an additional 3,959 shares in the last quarter. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Compugen during the second quarter valued at about $164,000. ProShare Advisors LLC increased its stake in shares of Compugen by 0.8% in the second quarter. ProShare Advisors LLC now owns 37,652 shares of the company’s stock valued at $244,000 after buying an additional 300 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Compugen by 2.2% in the second quarter. Janney Montgomery Scott LLC now owns 45,787 shares of the company’s stock valued at $293,000 after buying an additional 1,000 shares in the last quarter. Finally, Vident Investment Advisory LLC acquired a new stake in shares of Compugen during the second quarter valued at about $522,000. 14.11% of the stock is currently owned by institutional investors.

About Compugen

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

5 Day Chart for NASDAQ:CGEN

Receive News & Stock Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related stocks with our FREE daily email newsletter.